Chronic Lymphocytic Leukemia | Specialty

Using BCR-Targeted Agents for Relapsed/Refractory CLL

October 20th 2015

Anti-CD20 Antibodies for Chronic Lymphocytic Leukemia

October 20th 2015

Ongoing Role of Transplant in Chronic Lymphocytic Leukemia

October 20th 2015

Minimal Residual Disease in Chronic Lymphocytic Leukemia

October 20th 2015

Treating Younger and Older Patients With CLL

October 20th 2015

Initiating Therapy for Chronic Lymphocytic Leukemia

October 20th 2015

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

October 20th 2015

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL

October 20th 2015

John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib and idelalisib in chronic lymphocytic leukemia, as well as unanswered questions and challenges concerning these novel agents.

Long-Term Ibrutinib Data Show Durable Responses in Untreated and Relapsed/Refractory CLL

September 23rd 2015

Patients with untreated or relapsed/refractory chronic lymphocytic leukemia achieved durable responses with single-agent ibrutinib (Imbruvica).

FDA Grants Priority Review to Maintenance Ofatumumab in CLL

September 21st 2015

The FDA has granted a priority review designation to ofatumumab as a maintenance therapy for patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

Age, Health, Risk Define Treatment Groups and Options in CLL

September 18th 2015

Fitness, age, and disease risk status form the basis for decision-making about first-line therapy for chronic lymphocytic leukemia.

FDA Approval Sought for Frontline Ibrutinib in CLL

September 14th 2015

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLL

August 25th 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

Stephenson Cancer Center Aims for NCI Designation

August 21st 2015

Brentuximab Vedotin Label Expanded, Top-Line Results for CLL, NSCLC, and More

August 21st 2015

Venetoclax Achieves Primary Endpoint in Pivotal Phase II CLL Study

August 12th 2015

Treatment with single-agent venetoclax has met the primary endpoint of a pivotal phase II study for patients with relapsed or refractory chronic lymphocytic leukemia harboring the 17p deletion.

Researcher Responsible for CLL Breakthroughs Honored by ASH

July 31st 2015

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

Idelalisib Use Expands With New CLL Indication Pending

July 30th 2015

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

FDA Approval Sought for Maintenance Ofatumumab in CLL

July 23rd 2015

A supplemental biologics license application has been submitted to the FDA for ofatumumab as a maintenance therapy in patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

Dr. Jeffrey Jones on Idelalisib Combinations in CLL

July 22nd 2015

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses idelalisib (Zydelig) combinations in CLL.